Modeling restoration of gefitinib efficacy by co‐administration of MET inhibitors in an EGFR inhibitor‐resistant NSCLC xenograft model: A tumor‐in‐host DEB‐based approach-Reference-Cited by-同舟云学术

Modeling restoration of gefitinib efficacy by co‐administration of MET inhibitors in an EGFR inhibitor‐resistant NSCLC xenograft model: A tumor‐in‐host DEB‐based approach

Published:2021-10-28 Issue:11 Volume:10 Page:1396-1411
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst Pharmacol

Author:

Tosca Elena M.¹,Gauderat Glenn²,Fouliard Sylvain²,Burbridge Mike³,Chenel Marylore²,Magni Paolo¹

Affiliation:

1. Laboratory of Bioinformatics, Mathematical Modelling and Synthetic Biology Department of Electrical Computer and Biomedical Engineering Università degli Studi di Pavia Pavia Italy

2. Clinical Pharmacokinetics and Pharmacometrics Division Servier Suresnes France

3. Center for Therapeutic Innovation in Oncology Servier Suresnes France

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12710

Reference53 articles.

1. The biology and management of non-small cell lung cancer

2. Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

3. EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

4. Mechanisms of resistance to epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in NSCLC patients;Lin L;Chemother Res Pract,2012

5. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting Tumor Volume Doubling Time and Progression-Free Survival in Untreated Patients from Patient-Derived-Xenograft (PDX) Models: A Translational Model-Based Approach;The AAPS Journal;2024-08-08

2. Elevation of LEM Domain Containing 1 Predicts Poor Prognosis of NSCLC Patients and Triggers Malignant Stemness and Invasion of NSCLC Cells by Stimulating PI3K/AKT Pathway;Current Molecular Medicine;2024-03

3. Radius additivity score: a novel combination index for tumour growth inhibition in fixed-dose xenograft studies;Frontiers in Pharmacology;2023-10-13

4. A two-stages global sensitivity analysis by using the δ sensitivity index in presence of correlated inputs: application on a tumor growth inhibition model based on the dynamic energy budget theory;Journal of Pharmacokinetics and Pharmacodynamics;2023-07-09

5. Model-based assessment of combination therapies – ranking of radiosensitizing agents in oncology;BMC Cancer;2023-05-06